August 2012
-
The FDA has issued a revised draft guidance, “Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products – Quality Considerations.” The guidance is scheduled for publication in the Federal Register on April 19, 2018;… Read more . . .
-
Insys Therapeutics has announced that it plans to advance clinical research of a breath activated dronabinol (THC) inhaler in the second half of 2018. The company said that it plans to develop the inhaler for… Read more . . .
-
According to Opiant Pharmaceuticals, the National Institutes of Health’s National Institute on Drug Abuse (NIDA) has awarded the company a 3-year grant of about $7.4 million for development of OPNT003 intranasal nalmefene for the treatment… Read more . . .
-
US health insurer Highmark Inc. has announced that it signed an outcomes-based contract with AstraZeneca for Symbicort that provides for a rebate from AstraZeneca if the inhaler does not reduce COPD or asthma symptoms in… Read more . . .
-
Penthrox, a methoxyflurane inhaler, has been approved in Canada for short-term relief of moderate to severe pain resulting from trauma or medical procedures, Medical Developments International (MDI) said. The company announced in June 2017 that… Read more . . .
-
Pulmotect has closed on a $12 million Series B round to fund continued clinical development of its PUL-042 inhaled immune stimulant, the company said. Pulmotect has now received more than $25 million in funding for… Read more . . .
-
Pneuma Respiratory, which introduced a digital soft mist inhaler in November 2017, has announced the appointment of former Boehringer Ingelheim VP of Respiratory Products Steven Kesten as its new President and Chief Medical Officer. Since… Read more . . .
-
According to GSK and Innoviva, the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol DPI has been approved in Canada for the treatment of COPD in patients for whom treatment with an ICS/LABA combination is inadequate. Trelegy Ellipta should… Read more . . .
-
Sunovion Pharmaceuticals has launched Lonhala Magnair glycopyrrolate inhalation solution for the treatment of COPD in the US, the company said. Lonhala Magnair, also known as SUN-101/eFlow, was approved by the FDA in December 2017. In… Read more . . .
-
A Texas-based startup called TFF Pharmaceuticals announced that it raised $14 million in a Series A preferred stock offering and that it plans to use the funds for development of dry powder formulations for the… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.